Physician profile
Peter M Abel
NPI 1275530214
$3,885.22
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $323 · 2021: $297 · 2022: $1,029 · 2023: $938 · 2024: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,461.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $672.28 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $448.86 | 2022-2024 | Qulipta, Vraylar, Ubrelvy |
| Lilly USA, LLC | $422.82 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $397.69 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.65 | 2019-2024 | Jardiance |
| Amgen INC. | $234.59 | 2019-2024 | Repatha |
| Esperion Therapeutics, INC. | $162.48 | 2020-2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $153.66 | 2019-2023 | Breztri, Farxiga |
| Amarin Pharma, INC. | $148.68 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $148.06 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.29 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.24 | 2021-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $78.05 | 2019-2022 | |
| Exact Sciences Corporation | $76.57 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $57.97 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $51.72 | 2020 | |
| Abbott Laboratories | $48.76 | 2022-2023 | Freestyle Libre 3 |
| Arbor Pharmaceuticals, INC. | $47.73 | 2019 | |
| Merck Sharp & Dohme LLC | $45.32 | 2022 | |
| Glaxosmithkline, LLC. | $36.56 | 2019-2022 | |
| Circassia INC. | $28.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.82 | 2021-2023 | Eliquis |
| Nestle Healthcare Nutrition INC. | $22.81 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.06 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.27 | 2022 | |
| Allergan, INC. | $19.30 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.21 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.92 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $13.28 | 2021 | |
| Corcept Therapeutics | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Abel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.